APA (7th ed.) Citation

DJ, L., PL, H., SS, S., CC, V., J, V., SK, B., . . . EJ, K. (2021). Brentuximab Vedotin for Relapsed or Refractory Sézary Syndrome. JAMA dermatology, 157(3), 317. https://doi.org/10.1001/jamadermatol.2020.4901

Chicago Style (17th ed.) Citation

DJ, Lewis, et al. "Brentuximab Vedotin for Relapsed or Refractory Sézary Syndrome." JAMA Dermatology 157, no. 3 (2021): 317. https://doi.org/10.1001/jamadermatol.2020.4901.

MLA (9th ed.) Citation

DJ, Lewis, et al. "Brentuximab Vedotin for Relapsed or Refractory Sézary Syndrome." JAMA Dermatology, vol. 157, no. 3, 2021, p. 317, https://doi.org/10.1001/jamadermatol.2020.4901.